Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) EBIAT (2016 - 2017)

Historic EBIAT for Soleno Therapeutics (SLNO) over the last 5 years, with Q4 2017 value amounting to -$4.7 million.

  • Soleno Therapeutics' EBIAT fell 8150.06% to -$4.7 million in Q4 2017 from the same period last year, while for Dec 2017 it was -$15.4 million, marking a year-over-year decrease of 2751.54%. This contributed to the annual value of -$175.9 million for FY2024, which is 35116.45% down from last year.
  • Per Soleno Therapeutics' latest filing, its EBIAT stood at -$4.7 million for Q4 2017, which was down 8150.06% from -$3.8 million recorded in Q3 2017.
  • Soleno Therapeutics' EBIAT's 5-year high stood at $1.9 million during Q2 2015, with a 5-year trough of -$11.7 million in Q1 2015.
  • In the last 5 years, Soleno Therapeutics' EBIAT had a median value of -$2.9 million in 2015 and averaged -$3.3 million.
  • Data for Soleno Therapeutics' EBIAT shows a peak YoY increase of 16734.69% (in 2015) and a maximum YoY decrease of 129700.24% (in 2015) over the last 5 years.
  • Soleno Therapeutics' EBIAT (Quarter) stood at -$974243.0 in 2013, then crashed by 640.95% to -$7.2 million in 2014, then soared by 60.59% to -$2.8 million in 2015, then grew by 8.13% to -$2.6 million in 2016, then tumbled by 81.5% to -$4.7 million in 2017.
  • Its last three reported values are -$4.7 million in Q4 2017, -$3.8 million for Q3 2017, and -$4.0 million during Q2 2017.